PL378748A1 - Zastosowanie selektywnych agonistów receptora EP2 w leczeniu - Google Patents

Zastosowanie selektywnych agonistów receptora EP2 w leczeniu

Info

Publication number
PL378748A1
PL378748A1 PL378748A PL37874804A PL378748A1 PL 378748 A1 PL378748 A1 PL 378748A1 PL 378748 A PL378748 A PL 378748A PL 37874804 A PL37874804 A PL 37874804A PL 378748 A1 PL378748 A1 PL 378748A1
Authority
PL
Poland
Prior art keywords
medical treatment
receptor agonists
selective receptor
selective
agonists
Prior art date
Application number
PL378748A
Other languages
English (en)
Polish (pl)
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL378748A1 publication Critical patent/PL378748A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL378748A 2003-03-04 2004-02-23 Zastosowanie selektywnych agonistów receptora EP2 w leczeniu PL378748A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04

Publications (1)

Publication Number Publication Date
PL378748A1 true PL378748A1 (pl) 2006-05-15

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378748A PL378748A1 (pl) 2003-03-04 2004-02-23 Zastosowanie selektywnych agonistów receptora EP2 w leczeniu

Country Status (14)

Country Link
EP (1) EP1601351A1 (de)
JP (1) JP2006519250A (de)
KR (1) KR20050105511A (de)
CN (1) CN1859903A (de)
AU (1) AU2004216898A1 (de)
BR (1) BRPI0408061A (de)
CA (1) CA2518193A1 (de)
CL (1) CL2004000412A1 (de)
MX (1) MXPA05009398A (de)
NZ (1) NZ541828A (de)
PL (1) PL378748A1 (de)
TW (1) TW200424176A (de)
WO (1) WO2004078169A1 (de)
ZA (1) ZA200506532B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
JP5247675B2 (ja) 2006-03-24 2013-07-24 チルドレンズ メディカル センター コーポレーション 造血性幹細胞の増殖を調節する方法
NZ573964A (en) 2006-07-28 2010-11-26 Pfizer Prod Inc isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma
JP5426389B2 (ja) * 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション 組織の再生を亢進するための方法
CN101828111B (zh) * 2007-08-21 2014-07-23 塞诺米克斯公司 人t2r苦味受体及其用途
CN103965099A (zh) * 2008-03-12 2014-08-06 宇部兴产株式会社 吡啶基氨基乙酸化合物
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
CN102548985A (zh) * 2009-09-11 2012-07-04 宇部兴产株式会社 取代羰基化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
CN102498101A (zh) * 2009-09-11 2012-06-13 宇部兴产株式会社 苯胺化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
WO2011078303A1 (ja) 2009-12-25 2011-06-30 宇部興産株式会社 アミノピリジン化合物
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
HK1197238A1 (en) 2011-09-27 2015-01-09 雷迪博士实验室有限公司 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
CA2857640C (en) 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
EP2804605A4 (de) * 2012-01-20 2015-07-08 Acucela Inc Substituierte heterocyclische verbindungen zur behandlung von krankheiten
US20140142092A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
JPWO2014157672A1 (ja) 2013-03-28 2017-02-16 宇部興産株式会社 置換ビアリール化合物
EP4474384A1 (de) 2014-05-13 2024-12-11 Novartis AG Verbindungen und zusammensetzungen zur induktion von chondrogenese
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
CN115636761B (zh) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 一种油溶性表面活性剂、驱油剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
DK0951282T3 (da) * 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
JP2006519250A (ja) 2006-08-24
CN1859903A (zh) 2006-11-08
TW200424176A (en) 2004-11-16
AU2004216898A1 (en) 2004-09-16
BRPI0408061A (pt) 2006-02-14
KR20050105511A (ko) 2005-11-04
WO2004078169A8 (en) 2005-04-21
ZA200506532B (en) 2007-03-28
NZ541828A (en) 2008-06-30
MXPA05009398A (es) 2005-12-05
CA2518193A1 (en) 2004-09-16
EP1601351A1 (de) 2005-12-07
CL2004000412A1 (es) 2005-02-04
WO2004078169A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
PL378748A1 (pl) Zastosowanie selektywnych agonistów receptora EP2 w leczeniu
IL164778A0 (en) Therapeutic use of selective pde10 inhibitors
GB0403969D0 (en) Tissue treatment device
PL2625953T3 (pl) Udojowe urządzenie i sposób jego użycia
EP1793879A4 (de) Medizinisches hautapplikatorgerät
IL172418A0 (en) Therapeutic agents useful for treating pain
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
ZA200701193B (en) The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
PL1638628T3 (pl) Urządzenie do obróbki krwi
GB0324761D0 (en) Use of compounds in therapy
IL204561A (en) A device for treating body tissues with a drug substance
EP1515725A4 (de) Verwendung von cyclothiocarbamat-derivativen bei der behandlung von hormonabhängigen erkrankungen
PL378026A1 (pl) Leczenie chorób z zastosowaniem pełnych agonistów receptora Ó-7 nACh
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
PL1838301T3 (pl) Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe
IL175605A0 (en) Controlled release of topirimate in liquid dosage forms
IL178827A0 (en) Use of reboxetine for the treatment of pain
PL397023A1 (pl) Środek leczniczy do leczenia AIDS
EP1757241A4 (de) Chirurgische behandlungsvorrichtung
GB0415181D0 (en) Compounds for use in the treatment of infection
IL281624B1 (en) Ultrasound system for medical treatment
PL1799283T3 (pl) Urządzenie do obróbki krwi zawierające środek typu pręta do utrzymywania przedmiotów
GB2386839B (en) Apparatus for use in the treatment of choanal atresia
GB2419532B (en) Skin treatment device
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)